Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB3616 + TQB2450 is a combination therapy consisting of TQB3616, a novel CDK2/4/6 inhibitor, and TQB2450 (benmelstobart), a humanized IgG1 monoclonal antibody targeting PD-L1. TQB3616 works by inhibiting cyclin-dependent kinases 2, 4, and 6, showing enhanced tumor killing effects by promoting cell apoptosis and inducing G1 cell cycle arrest. TQB2450 targets the PD-L1 immune checkpoint, potentially enhancing anti-tumor immune responses. This combination is being investigated for potential synergistic effects in cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TQB3616 + TQB2450.